Five Dividend Stocks to Follow Hedge Funds Into
Dividend yield is a very important metric that should be taken into account when picking a stock.
Posts Tagged ‘NYSE:BMY’
Market Movers Today: Corcept Therapeutics Incorporated (CORT), Eyegate Pharmaceuticals Inc (EYEG), Arconic Inc (ARNC), and More
Shares of Corcept Therapeutics Inc.
5 Stocks Insiders and Hedge Funds Are Crazy About
2017 has come to a close and it's been a wildly successful year for the stock market, as the S&P 500 jumped by 19% excluding dividends, the NASDAQ shot up by 28%, and the Dow ...
10 Biggest Antidepressant Drug Companies In 2017
The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide...
Opus Point Partners’ AUM, History and Investments
Opus Point Partners was founded by Michael S. Weiss and Dr. Lindsay A. Rosenwald in 2009. Prior to launching Opus Point Partners, Mr. Weiss and Dr.
With Stock Returns Of Over 205% in the Last Year, This Fund Is Proof That Hedge Funds Aren’t Going Anywhere
If someone is looking for convincing arguments about the wildly publicized doom of the hedge fund business, they don’t need to look far beyond the 2017 list of the highest paid...
Here’s Why Wells Fargo, eBay, CytomX Therapeutics, Dominion Diamond, and More Are Trending
The markets are relatively quiet today as there are no major economic releases. The Dow Jones index is down 10 points, while the S&P 500 is 0.23% in the red.
Billionaire Barry Rosenstein’s Top Q4 Moves: Alphabet (GOOG), Bristol-Myers (BMY), More
Founded in 2001, JANA Partners is led by billionaire Barry Rosenstein, along with co-portfolio managers David DiDomenico and Scott Ostfeld.
Director at Giant Drugmaker Buys New Stake Amid Takeover Speculations and Activist Pressure, Plus Other Insider Trading
Insider trading can be either legal or illegal.
Billionaire Julian Robertson Bets Big on Technology Sector With These Stocks
Julian Robertson is an iconic hedge fund manager who started Tiger Management in 1980.
Bristol-Myers Squibb Co (BMY) To Sell Senior Notes As Formidable Activist Investor Shows Interest
Bristol-Myers Squibb Co (NYSE:BMY) will sell senior notes that are unsecured worth $1.5 billion.
Bristol-Myers Squibb Co (BMY), Merck & Co., Inc. (MRK), And Other Pharmaceutical Firms All Targeting I-O Segment
Reports indicate that the market for immuno-oncology drugs could grow to $25 billion in the next ten years.
Here Are The Major Moves Made By Bridgewater Associates Going Into 2017
2016 was again a dismal year for the hedge fund industry, with a lot of hedge funds failing to beat the benchmark and some trailing it by a huge margin.
Bristol-Myers Squibb Co (BMY) To Share In Sales Of Merck & Co., Inc. (MRK) Keytruda Following Litigation Settlement
Merck & Co., Inc. (NYSE:MRK) has agreed to share a portion of Keytruda sales with Bristol-Myers Squibb Co (NYSE:BMY) and Ono Pharmaceutical Co., Ltd.
Bristol-Myers Squibb Co (BMY) Agrees To Extend Research With Five Prime Therapeutics Inc (FPRX)
Bristol-Myers Squibb Co (NYSE:BMY) has opted to extend the research term of its discovery collaboration agreement with Five Prime Therapeutics Inc (NASDAQ:FPRX).
Gilead Sciences, Inc. (GILD) Is A Hail Mary: 3 Better Stocks To Consider
After a strong 2015, health care stocks are leading the way lower in 2016. And it’s been an even uglier year for biotechnology company Gilead Sciences, Inc.
Bristol-Myers Squibb Co (BMY) And Pfizer Inc. (PFE) Agree To $50 Million Loan To Portola Pharmaceuticals Inc (PTLA)
There is a need for additional funding towards the development and clinical studies of AndexXa, a new compound that is a prospective antidote for Factor Xa inhibitors.
5 Healthcare Stocks Billionaires Are Buying
Billionaire investors are successful for a reason. They do not funnel their money in ordinary places.
D E Shaw Makes Massive Investments in Apple, Disney, More
David E. Shaw is an American computer scientist and investor who founded D.E. Shaw & Co., L.P. in 1988. The hedge fund manages a 13F portfolio of over $59.68 billion. David E.
$50 Billion Quant Fund Is Making New Bets On These Stocks
Renaissance Technologies is probably the best quant hedge fund in the market.
Is Bristol Myers Squibb Co. (BMY) Worthy Of Your Portfolio?
Like everyone else, elite investors make mistakes.
A Look At Billionaire Julian Robertson’s Top Dividend Picks
Hedge fund legend Julian Robertson closed his hedge fund Tiger Management to outside investors way back in 2000 and has been using it as a vehicle to manage his own money since...
Billionaire Julian Robertson Takes Out Huge SPY Hedge, Grows Bearish on Transportation Stocks
Tiger Management is a New York-based hedge fund founded in 1980 by legendary investor and billionaire Julian Robertson.
Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare Sector Paid Off?
Opus Point Partners Management is a New York-based fund led by Michael S. Weiss and Lindsay A. Rosenwald.
Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up On Opdivo Combination Therapy
Bristol-Myers Squibb Co (NYSE:BMY) and Infinity Pharmaceuticals Inc.
Scout Daily Update: Core Durable Goods Down 21 Straight Months
Twitter Inc (NYSE:TWTR): reported Q3 EPS of $0.13 which beat estimates by 4 cents. Revenue of $616 million was up 8.2% which beat estimates by $10.16 million.
Here’s Why Bristol-Myers Squibb Co (BMY), Telefonica Brasil SA (ADR) (VIV) and Three Other Stocks Plunged on Monday
Markets are trading on an optimistic note as all the major indices are in green zone.
VeriFone (PAY), Gilead (GILD) Among 5 Stocks That Hit 52-Week Lows Last Week
In this article we'll take a look at why VeriFone Systems Inc (NYSE:PAY), Dynavax Technologies Corporation (NASDAQ:DVAX), Gilead Sciences, Inc.
Why Do Hedge Funds Like Five Prime Therapeutics?
Five Prime Therapeutics Inc (NASDAQ:FPRX) is a $1.25 billion biotech company that focuses on the discovery and development of protein therapeutics that block cancer and inflammatory...
Why Dean Foods, Bristol-Myers, and Three Other Stocks Are on the Move Today
US stocks are trading slightly lower on Monday afternoon, as the major indexes retrieved from all-time highs reached on Friday, and a spike in energy stocks was not enough to ...
10 NYSE Stocks Hitting 52-Week Highs Tuesday
Bull sentiment dominated the markets during the first two trading sessions of the week, thanks to growing optimism about economic growth in the U.S after a strong jobs report, ...
Cheniere Energy Inc. (LNG) and Vince Holding Corp (VNCE) See Their CEOs Buy Shares; Three Other Companies Register Insider Selling
While there is no way to either deny or confirm the following statement, there is good reason to believe that hedge fund vehicles usually do not pay too much attention to insider...
The Highest-Earning Hedge Fund Manager in 2015 Reveals His Top Stock Picks for Q2
Chicago billionaire Ken Griffin, the Founder and Chief Executive Officer of Citadel Advisors, was the highest-paid hedge fund manager in 2015, earning a stunning $1.7 billion ...
Here’s Why Investors Are Watching These Five Stocks Today
It's the middle of earnings season and many investors are hungrily dissecting earnings reports and management commentary to get a better view on earnings outlooks for the future...
Stocks Financial Advisors Are Interested In: Costco, Facebook & More
Last week was marked by the S&P 500 entering into its eighth year of bull run amid an increase in oil prices and hopes of more stimulus from central banks.
Is Bristol Myers Squibb Co. (BMY) Going to Burn These Hedge Funds?
Hedge fund managers like David Einhorn, Dan Loeb, and Carl Icahn became billionaires by reaping large profits for their investors, which is why piggybacking their stock picks ...
Hedge Funds Are Buying These 10 Large-Caps, Part 2
Large-cap stocks are generally less immune to sharp moves based on rumors than their mid and small-cap counterparts.
Here is What Hedge Funds Think About Bristol Myers Squibb Co. (BMY)
You probably know from experience that there is not as much information on small-cap companies as there is on large companies.
Sector Concerns Not Scaring Clifford Fox Away From These 5 Healthcare Stocks
Clifford Fox's Columbus Circle Investors is a multi-billion dollar investment management firm that has been primarily successful in picking small-cap and mid-cap stocks over ...
Why Are These Stocks Surging Today?
It's Thursday and shareholders of BofI Holding, Inc.
Medtronic PLC (MDT), Actavis plc (ACT): Zweig-DiMenna Partners Top Picks from Healthcare Sector
Zweig-DiMenna Partners is a US-based hedge fund managed by Joseph A. DiMenna, who co-founded the fund with Martin Zweig back in 1984.
Healthcare Hedge Fund Orbimed’s Top Picks and New Move
According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals...
Bristol-Myers Squibb Co (BMY) Sues Merck & Co., Inc. (MRK) Over Cancer Drug, Position Strong
Bristol-Myers Squibb Co (NYSE:BMY) along with Ono Pharmaceutical launched a lawsuit against Merck & Co., Inc.
Intercept Pharmaceuticals Inc. (ICPT), Bristol-Myers Squibb Co (BMY), Biogen Idec Inc (BIIB): Orbimed Advisors Top Stocks in Q2
Orbimed Advisors, led by Samuel Isaly, recently published its 13F filing with the U.S. Securities and Exchange Commission.
David Kim’s Ghost Tree Capital Loves These Healthcare Stocks
Ghost Tree Capital is a healthcare-oriented hedge fund headquartered in New York.
Druckenmiller’s 4Q13 Portfolio Changes
Stan Druckenmiller is a billionaire, and was the long-time manager of Duquesne Capital. Now, he oversees a family office, but his investing strategy is mostly the same.
Billionaire Stan Druckenmiller’s Top Stock Picks
In a latest 13F filing, Stanley Druckenmiller’s fund Duquesne Capital, revealed its holdings for the fourth quarter of 2013.
The Pharmaceutical Industry’s 10 Biggest R&D Budgets
Innovation is everything when it comes to the pharmaceutical sector.
AstraZeneca plc (ADR) (AZN), Merck & Co., Inc. (MRK), Endocyte, Inc. (ECYT): Three Things You Need to Know About This Big Pharma Deal
Through the years, London-based drugmaker AstraZeneca plc (ADR) (NYSE:AZN) and U.S. pharmaceutical firm Merck & Co., Inc.
Bristol Myers Squibb Co. (BMY), Merck & Co., Inc. (MRK): Is AstraZeneca plc (ADR) (AZN)’s Recent Acquisition Bigger Than Onyx?
AstraZeneca plc (ADR) (NYSE:AZN) may have missed out on acquiring the oncology platform of Onyx Pharmaceuticals, but it responded by pulling the trigger on a $500 million deal...
